Trends and correlates of cocaine use and cocaine use disorder in the United States from 2011 to 2015

John, William S.; Wu, Li‐Tzy

doi:10.1016/j.drugalcdep.2017.08.031

Cited by 112 publications

(78 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cannabis, opioids, and cocaine constitute the greatest proportion of these diagnoses (5). Recent trends have shown increased adult use of cannabis (6)(7)(8), opioids (9)(10)(11), and stimulant drugs (12,13), and associated adverse public health outcomes (3).…”

Section: Introductionmentioning

confidence: 99%

“…The United States has recently seen unprecedented levels of opioid misuse and overdose deaths, including a notable increase in prescription opioid misuse between 2001 and 2013 (17), and over 42,000 opioid-related deaths in 2016 (3). Additionally, recent increases in cocaine and other stimulant use (13,(18)(19)(20) have contributed to a substantial number of hospitalizations (21,22) and deaths (3).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

et al. 2020

View full text Add to dashboard Cite

Background: Observational data and preliminary studies suggest serotonin 2A agonist psychedelics may hold potential in treating a variety of substance use disorders (SUDs), including opioid use disorder (OUD). Aims: The study aim was to describe and analyze self-reported cases in which naturalistic psychedelic use was followed by cessation or reduction in other substance use. Methods: An anonymous online survey of individuals reporting cessation or reduction in cannabis, opioid, or stimulant use following psychedelic use in non-clinical settings. Results: Four hundred forty-four respondents, mostly in the USA (67%) completed the survey. Participants reported 4.5 years of problematic substance use on average before the psychedelic experience to which they attributed a reduction in drug consumption, with 79% meeting retrospective criteria for severe SUD. Most reported taking a moderate or high dose of LSD (43%) or psilocybin-containing mushrooms (29%), followed by significant reduction in drug consumption. Before the psychedelic experience 96% met SUD criteria, whereas only 27% met SUD criteria afterward. Participants rated their psychedelic experience as highly meaningful and insightful, with 28% endorsing psychedelic-associated changes in life priorities or values as facilitating reduced substance misuse. Greater psychedelic dose, insight, mystical-type effects, and personal meaning of experiences were associated with greater reduction in drug consumption. Conclusions: While these cross-sectional and self-report methods cannot determine whether psychedelics caused changes in drug use, results suggest the potential that psychedelics cause reductions in problematic substance use, and support additional clinical research on psychedelic-assisted treatment for SUD.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Cocaine use in older adults is on the rise [1][2][3]. Estimates suggest the prevalence of weekly cocaine use and CUD among individuals ≥ 50 increased from 2011−2015 at a rate of 236% and 271%, respectively [4]. Aging is associated with decreased health and a significant changes in immune functioning called 'immunosenescence'.…”

Section: Introductionmentioning

confidence: 99%

Elevated Neutrophil to Lymphocyte Ratio in Older Adults with Cocaine Use Disorder as a Marker of Chronic Inflammation

Soder¹,

Berumen²,

Gomez³

et al. 2020

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Objective: The neutrophil to lymphocyte ratio (NLR) is a non-specific, easy-to-obtain marker of inflammation associated with morbidity and mortality in systemic, psychiatric, and age-related inflammatory conditions. Given the growing trend of substance use disorder (SUD) in older adults, and the relationship between inflammation and SUD elevated NLR may serve as a useful inflammatory biomarker of the combined burden of aging and SUD. The present study focused on cocaine use disorder (CUD) to examine if cocaine adds further inflammatory burden among older adults, by comparing NLR values between older adults with CUD and a non-cocaine using, aged-matched, nationally representative sample. Methods: The dataset included 107 (86% male) participants (aged 50−65 years) with cocaine use disorder. NLR was derived from complete blood count tests by dividing the absolute value of peripheral neutrophil concentration by lymphocyte concentration. For comparison, we extracted data from age-matched adults without CUD using the National Health and Nutrition Examination Survey. Individuals with immunocompromising conditions were excluded (e.g., rheumatoid arthritis and sexually transmitted infections such as HIV). A doubly-robust inverse probability-weighted regression adjustment (IPWRA) propensity score method was used to estimate group differences on NLR while controlling for potential confounding variables (age, gender, race, income, nicotine, marijuana and alcohol use). Results: The IPWRA model revealed that the CUD sample had significantly elevated NLR in comparison to non-cocaine users, with a moderate effect size ( weight = 0.67). Conclusion: Although non-specific, NLR represents a readily obtainable inflammatory marker for SUD research. CUD may add further inflammatory burden to aging cocaine users.

show abstract

“…Los pacientes diagnosticados con trastorno por consumo de cocaína (TCC) sufren complicaciones que incluyen problemas médicos, deterioro familiar y social, desempleo, y trauma físico y sexual. Dichas complicaciones se ven acentuadas en poblaciones de alto riesgo, como mujeres, personas mayores, y policonsumidores (John y Wu, 2017). Es más, varios estudios en población con TCC han señalado una alta prevalencia -más del 40%-de comorbilidad psiquiátrica (Araos et al, 2014;Herrero, Domingo-Salvany, Brugal, Torrens y ITINERE Investigators, 2011;Herrero, Domingo-Salvany, Torrens, Brugal y ITINERE Investigators, 2008).…”

unclassified

Trastorno por uso de cocaína y depresión: Cuando el diagnóstico clínico no es suficiente

et al. 2020

View full text Add to dashboard Cite

Antecedentes: El consumo de cocaína es un creciente problema de salud en todo el mundo. Además, los pacientes con trastorno por consumo de cocaína (TCC) presentan una alta comorbilidad con el trastorno depresivo mayor (TDM). Estos pacientes pueden presentar dos tipos de TDM: trastorno depresivo mayor primario (TDM-P) y trastorno depresivo mayor inducido por cocaína (TDM-IC). El objetivo de este estudio es evaluar las diferencias en la sintomatología depresiva (TDM-P vs. TDM-IC) en los pacientes con TCC para mejorar su tratamiento. Métodos: Se llevó a cabo un análisis secundario en una muestra transversal de 160 pacientes que presentaban TCC y algún TDM. La evaluación clínica, así como el diagnóstico diferencial entre TDM-P y TDM-IC, se realizó utilizando la entrevista PRISM. Resultados: Los hombres representaron el 80% de la muestra con una edad media de 38,61 años y el 64,5% sólo tenía estudios primarios. El diagnóstico de TDM-IC (61,3%) fue más frecuente que el de TDM-P (38,7%). Los pacientes con TDM-IC mostraron una edad de aparición más temprana para el TCC. El 79,4% de los pacientes cumplían criterios para otro trastorno por consumo de sustancias. Únicamente el criterio "Cambios en el peso o en el apetito" fue estadísticamente más prevalente (57,1%) en los pacientes con TDM-P.Conclusiones: Existen diferencias en el criterio "Cambios en el peso o en el apetito" entre TDM-P y TDM-IC. Se necesita más investigación a fin de obtener un diagnóstico diferencial entre los dos tipos de depresión y proporcionar un mejor tratamiento para los pacientes con TCC. Palabras clave: Patología dual; Trastorno por uso de cocaína; Trastornos relacionados con el uso de cocaína; Trastorno depresivo; Trastorno depresivo inducido. Background: Cocaine use is a growing global health problem and patients with cocaine use disorders (CUD) present several complications, including high rates of major depression. These subjects present two types of major depressive disorder (MDD): primary major depressive disorder (P-MDD) and cocaine-induced major depressive disorder (CI-MDD). To improve treatment, it is necessary to distinguish between both types. The aim of this study was to assess the differences in depressive symptomatology criteria (P-MDD vs CI-MDD) in CUD patients. Methods: Secondary data analysis was carried out with a cross-sectional sample of 160 patients presenting CUD and MDD. Clinical assessment was performed using the Psychiatric Research Interview for Substance and Mental Disorders (PRISM). A differential diagnosis was obtained between P-MDD and CI-MDD. Results: Menrepresented 80% of the sample, the mean age was 38.61 years, and 64.5% had elementary studies. CI-MDD diagnosis (61.3%) was more frequent than P-MDD (38.7%). There was a younger age of CUD onset in CI-MDD patients. In addition, 79.4% of the patients had another substance use disorder diagnosis. The criterion "Changes in weight or appetite" was more prevalent (57.1%) in P-MDD group. Conclusions:We found differences in the criterion "Changes in weight or appetite".Fur...

show abstract

Trends and correlates of cocaine use and cocaine use disorder in the United States from 2011 to 2015

Cited by 112 publications

References 52 publications

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey

Elevated Neutrophil to Lymphocyte Ratio in Older Adults with Cocaine Use Disorder as a Marker of Chronic Inflammation

Trastorno por uso de cocaína y depresión: Cuando el diagnóstico clínico no es suficiente

Contact Info

Product

Resources

About